Born 1980. Active in the company since 2006. Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Chair of Biosergen AB and as a Board member of Saniona AB.
Shareholding: 69 806 shares and 388 264 performance share units that can entitle a maximum of 314 799 shares.
Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets.
Shareholding: 46 646 shares and 312 958 performance share units that can entitle a maximum of 216 079 shares.
Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems. Mark is Board member of Loaded Dice AB.
Shareholding: 88 931 shares and 312 958 performance share units that can entitle a maximum of 216 079 shares
Born 1970. Dr Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University.
Shareholding: 0 shares and 82 958 performance share units that can entitle a maximum of 100 379 shares.
Born 1966. Active in the company since 2026. Lars has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB.
Shareholding: 0 shares. Independent in relation to the company and the owners.
Born 1991. Active in the company since 2026. Jack has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen.
Shareholding: 0 shares but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the company and the owners.
Born 1968. Active in the company since 2026. Daniel has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc (HROW), Delcath Systems Inc (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy.
Shareholding: 1 409 456 shares. independent from the company and owners.
Born 1969. Active in the company since 2025. Isabelle Ducellier is a dual citizen of France and Sweden. She has over 30 years of experience in building global brands in highly international environments. She began her career in the wine and spirits industry but has focused on consumer health since 2017. She has served as Secretary General of the Swedish Childhood Cancer Fund, CEO of the world-leading probiotic company BioGaia, and most recently CEO of Orkla Health—a key European player in VMS (Vitamins, Minerals, and Supplements), oral health, and a global manufacturer of wound care and first aid products.
Shareholding: 10 512 shares. Independent in relation to the company and the owners.
Born 1982. Active in the company since 2025. Richard has more than 15 years of experience in global equity investment and maximizing shareholder value. Richard is also a serial entrepreneur who has co-founded, acquired and developed multiple businesses across finance, direct-to-consumer (DTC) goods, and healthcare. Richard currently serves as the CEO of How100.ai and Goldenwise Capital Group, as well as the Managing Director of BalanceGenics and The Stretching Institute of America. Richard holds an M.Sc. in Financial Mathematics from the University of British Columbia, Canada.
Shareholding: 2 649 037 shares. Independent from the company and owners.
Born 1970. Active in the company since 2025. Fredrik Blom holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties.
Shareholding: 926,000 shares. Independent in relation to the Company and the owners.